Igor Boechat Silveira

Mr. Igor Boechat Silveira

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2025 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
BMBernardo de Faria Moraes
Bernardo de Faria Moraes
GLGustavo André Pedral Diniz Leite
Gustavo André Pedral Diniz Leite
ISIgor Boechat Silveira
Igor Boechat Silveira
NLNathália Veloso Lana
Nathália Veloso Lana
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado

21 May 2026 in Liver International
Verified
Journal Article
Open access
IVIsabelle Castro Vitor
Isabelle Castro Vitor
MTMilena Tome
Milena Tome
WAWellgner Fernandes Oliveira Amador
Wellgner Fernandes Oliveira Amador
ISIgor Boechat Silveira
Igor Boechat Silveira
MLMarina de Assis Bezerra Cavalcanti Leite
Marina de Assis Bezerra Cavalcanti Leite
RMRodrigo Vieira Motta
Rodrigo Vieira Motta
Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485

22 October 2025 in American Journal of Transplantation
Verified
Journal Article
Closed access
PPPedro Passos
Pedro Passos
VFValbert Oliveira Costa Filho
Valbert Oliveira Costa Filho
MNMariana Macambira Noronha
Mariana Macambira Noronha
YRYohanna Idsabella Rossi
Yohanna Idsabella Rossi
IVIsabelle Castro Vitor
Isabelle Castro Vitor
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado

25 August 2025 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
ISIgor Boechat Silveira
Igor Boechat Silveira
RRRodolfo Augusto Assis Rezende
Rodolfo Augusto Assis Rezende
CNCarlos Alberto Monteiro Leitão Neto
Carlos Alberto Monteiro Leitão Neto
YRYohanna Rossi
Yohanna Rossi
MLMarina de Assis Bezerra Cavalcanti Leite
Marina de Assis Bezerra Cavalcanti Leite
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
Background: Autoimmune cholestatic liver diseases (AICLDs), including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), are characterized by progressive biliary injury and cholestasis, leading to an impaired quantity/quality of life. Pruritus affects 20–70% of patients and is often refractory to current treatments. Ileal bile acid transporter (IBAT) inhibitors reduce bile acid reabsorption and may alleviate cholestatic pruritus. This systematic review and meta-analysis evaluates their efficacy and safety in adults with AICLD. Methods: Following PRISMA guidelines, we systematically searched PubMed, Embase, and Cochrane-CENTRAL for studies assessing IBAT inhibitors in adult AICLD patients with pruritus for ≥12 weeks. The primary outcome was the change in the 5-D Pruritus Scale. Secondary outcomes included sleep quality, serum bile acids, liver biochemistry, and safety. Heterogeneity was assessed using Cochrane Q and I2 statistics. Results: Three studies (n = 180) met inclusion criteria, including two RCTs and one single-arm study. Patients (78% female; 85% PBC; 77% linerixibat) showed a significant pruritus reduction (MD = −4.93, 95%CI [−6.26, −3.59], p < 0.0001), accompanied by improved sleep quality (MD = −8.12, 95%CI [−13.54, −2.70], p = 0.0033). Serum bile acids, FGF19, and autotaxin decreased significantly, with increased C4 levels. AST and GGT declined, while ALP, ALT, and bilirubin remained stable. Adverse events occurred in 89.7%, mainly diarrhea (22.7%), nausea (12.2%), and abdominal pain (18.2%); serious events were rare (2.2%). Conclusions: IBAT inhibitors significantly reduce pruritus and improve sleep in AICLD, with a favorable safety profile. These findings support their potential as a novel therapeutic option for cholestatic pruritus in adults with AICLD.

16 February 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BMBernardo de Faria Moraes
Bernardo de Faria Moraes
ISIgor Boechat Silveira
Igor Boechat Silveira
GLGabriel André Pedral Diniz Leite
Gabriel André Pedral Diniz Leite
MFMaria Luisa Motta Fonseca
Maria Luisa Motta Fonseca
LSLeonardo Corrêa Suffert
Leonardo Corrêa Suffert
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado

24 September 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
ISIgor Boechat Silveira
Igor Boechat Silveira
LSLeonardo Corrêa Süffert
Leonardo Corrêa Süffert
GLGustavo André Pedral Diniz Leite
Gustavo André Pedral Diniz Leite
MTMilena Tome
Milena Tome
SLSarah Quick Lourenço de Lima
Sarah Quick Lourenço de Lima
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974